Engitix Therapeutics of the UK has made two new appointments to its management team. Alan Holmes joins the company as senior director, fibrosis, and John Prime has been named director, computational biology. Dr Holmes joins from UCB SA where he was director, drug target identification. He has previously worked at GlaxoSmithKline Plc and at University College London, where he received his PhD in 2007. Dr Prime has more than 10 years of bioinformatics experience and joins Engitix from Horizon Discovery Group Plc.
Engitix Therapeutics announced the appointments on 23 February 2021.
Copyright 2021 Evernow Publishing Ltd